Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ACN 080 699 065) serves as a Notice of Annual General Meeting (AGM) and accompanying Explanatory Memorandum. The filing date is October 12, 2015, for the month of October 2015. The AGM is scheduled for November 13, 2015, to consider the 2015 Annual Financial Statements for the year ended June 30, 2015, and to vote on several resolutions regarding corporate governance, capital raising, and employee incentives.
Key Financial Metrics
The filing does not provide a full income statement, balance sheet, or cash flow statement. However, it discloses specific capital raising data from the preceding 12 months:
- Capital Raised: Approximately A$7.11 million (specifically A$7,109,583) was raised between February 2015 and May 2015.
- Shares Issued: 44,954,510 fully paid ordinary shares were issued via an At-The-Market (ATM) facility.
- Issue Price Range: Shares were issued at prices ranging from A$0.1408 to A$0.2151 per share.
- Use of Proceeds: Funds are designated for working capital, research programs, and current clinical development in neurodegeneration.
- Share Plan Pool: The company seeks to refresh a pool of 60,000,000 securities for employee incentives. As of the filing, 44,440,798 securities (shares and options) have been utilized from the previous pool.
Material Changes and Capital Activities
The primary material activity disclosed is the recent capital raising program. The company issued 44,954,510 shares (representing 9.19% of shares on issue 12 months prior) under an ATM facility managed by McNicoll, Lewis & Vlak LLC. These shares were sold to professional investors and via NASDAQ on-market transactions. The filing notes that as of the date of the notice, the funds raised from these issues have not yet been spent.
Guidance, Outlook, and Resolutions
The filing outlines five key resolutions for shareholder approval:
- Remuneration Report: Non-binding adoption of the remuneration report for the year ended June 30, 2015.
- Director Re-election: Re-election of Dr. George Mihaly, who retires by rotation.
- Ratification of ATM Issue: Ratification of the 44,954,510 shares issued under the ATM facility to comply with ASX Listing Rule 7.4.
- Employee Share Plan Refresh: Approval to refresh the 2004 ASX and ADS Share Plans to issue remaining approved shares (15,559,202) that would otherwise expire.
- 10% Placement Facility: Special resolution to approve the ability to issue equity securities up to 10% of issued capital over the next 12 months under ASX Listing Rule 7.1A. The company currently has no specific plans to utilize this facility but seeks the flexibility for future funding or acquisitions.
Risks and Contingencies: The filing highlights the risk of dilution to existing shareholders if the 10% placement facility is utilized. It also notes that the market price of securities may be lower on the date of any future issue, affecting the total funds raised.
Investor Verification Checklist
- Verify the full 2015 Annual Financial Report (not included in this filing) to assess the company's cash burn rate and liquidity position.
- Confirm the status of clinical development programs in neurodegeneration to validate the use of the A$7.11 million raised.
- Review the specific terms of the 2004 ADS and ASX Share Plans to understand the dilution impact of the proposed refresh.
- Monitor the company's utilization of the proposed 10% placement facility, as it could significantly impact share capital and voting power.
- Check the outcome of the AGM on November 13, 2015, specifically regarding the ratification of the ATM issue and the 10% placement approval.